This is justifiable nonetheless since bevacizumab displays linear pharmacokinetics, yielding similar exposure with flexible dosage regimens administered on a mg/kg basis such as bi- or three-weekly dosing.16 Pharmaco-dynamic information collected during clinical trials in phase I to III studies of bevacizumab showed that under treatment with bevacizumab at different dosages, e.g. at a dose of 2.5 mg/kg per week in colorectal cancer and at 5.0 mg/kg per week in breast cancer circulating VEGF levels were un-measurable.17,18. This evidence concerns the gene VEGFA and colorectal cancer.